Notizia - Recent Pharma, Healthcare and Biotech Happenings

recent-pharma-happenings-for-pfizer-abcellera-sarepta-eli-lilly

Pfizer hit by DMD delay & halts BCMA trials; Sarepta’s drug shows promise in Phase II; Human organ chips enable COVID-19 drug repurposing; AbCellera takes new antibody into clinic

Pfizer suffers a DMD delay and halts BCMA trials amid safety woes Pfizer has paused after seeing three cases of peripheral neuropathy in an early-stage study, enrollment in a critical analysis of its anti-BCMA bispecific antibody. Big Pharma shares news with details of delays to the start of the US part of Duchenne Muscular Dystrophy (DMD) Phase 3. In February, Pfizer announced a crucial phase in the strength of the overall response rate of 80% seen in 20 patients treated with BCMA bispecific elanatamab, also known as PF-06863135, in Phase 1. 2 Incorporated into research. In a study of patients with relapsed and refractory multiple myeloma, Pfizer suspende...

Explore More...

Regeneron/Sanofi’s PD-1 drug candidate; Zika targeting drugs and vaccines developments; CMO of Achillion will leave this month; Lincoln’s anti-malarial drug

Therapeutics and Celgene to develop therapies; Takeda’s expansion; J&J hopes to limit; Tech Prize for genome sequencing; Endocyte’s late-stage prostate cancer deal

Alzeimer’s drug; Guardant Health receives approval; First Patient Dosed in Phase 1 Clinical Trial; Sunny Pharmtech and Vitruvias Therapeutics Receive FDA Approval

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Pfizer hit by DMD delay & halts BCMA trials; Sarepta’s drug shows promise in Phase II; Human organ chips enable COVID-19 drug repurposing; AbCellera takes new antibody into clinic

Regeneron/Sanofi’s PD-1 drug candidate; Zika targeting drugs and vaccines developments; CMO of Achillion will leave this month; Lincoln’s anti-malarial drug

Roche’s Phase 2 data; Celgene and Bluebird’s CAR-T therapy; Regeneron/Sanofi gets results; Allergan on women’s health

December 7 Business Cocktail

KINECT 4 Study; KindredBio Announces Results; Mylan and Aspen’s Launch; EMA investigates; Amgen’s Repatha

Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial

EMA to relocate to Amsterdam; Roche’s prospects; Amgen’s Humira Biosimilar delayed; Purdue’s opioid lawsuit

Novartis ventures; Bill Gates invests; Arcus Biosciences gains; Denali and Odonate seek funding; Fosun Pharma acquires

Business Cocktail

More Views & Analysis

Teva sells generics; Valeant trades; Roche’s Genentech; J&J’s next potential frontier

AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes

Novo petitions FDA;J&J invests; Xarelto’s trial; Roche’s Tecentriq

C-X-C Chemokine Receptor Inhibitors–The Emerging Therapeutic Agents

Therapeutics and Celgene to develop therapies; Takeda’s expansion; J&J hopes to limit; Tech Prize for genome sequencing; Endocyte’s late-stage prostate cancer deal

Alzeimer’s drug; Guardant Health receives approval; First Patient Dosed in Phase 1 Clinical Trial; Sunny Pharmtech and Vitruvias Therapeutics Receive FDA Approval

Business Cocktail

Thrombolytic Sciences’ trial; NurOwn for ALS; Biosimilar receives approval; Trelegy Ellipta for the treatment of COPD

Subscribe to our Updates

Daily

Weekly

Monthly